@article{2d978ae662d4451386d6b4febc5c0d5d,
title = "Acalabrutinib for treatment of diffuse large B-cell lymphoma: Results from a phase Ib study",
author = "Paolo Strati and {de Vos}, Sven and Jia Ruan and Maddocks, {Kami J.} and Flowers, {Christopher R.} and Simon Rule and Priti Patel and Yan Xu and Helen Wei and Frigault, {Melanie M.} and Roser Calvo and Dyer, {Martin J.S.}",
note = "Funding Information: Contributions: all authors contributed to data interpretation, reviewed and provided important intellectual contributions to the manuscript, and approved the final version for publication. Statistical analyses were performed by HW. Funding: the study was funded by Acerta Pharma, South San Francisco, CA, a member of the AstraZeneca Group. Medical writing assistance, funded by Acerta Pharma, was provided by James Street, PhD, and Jennifer Darby, PharmD, of Peloton Advantage, LLC, an OPEN Health company. PS{\textquoteright}s salary is supported by the Lymphoma Research Foundation Career Development Award.",
year = "2021",
month = oct,
doi = "10.3324/haematol.2021.278654",
language = "English (US)",
volume = "106",
pages = "2775--2778",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "10",
}